Stryker (SYK) Could Be 13% Undervalued After Cyberattack And Vision Pro Milestone
Stryker (SYK) is in focus after two contrasting developments. The company completed the first hip arthroscopy using its SportSuite Vision on Apple Vision Pro and is managing ongoing supply disruptions following a March cyberattack.
Against that backdrop, Stryker’s share price has been under pressure, with a 7-day share price return of down 12.33% and a 30-day share price return of down 22.44% as investors weigh the cyberattack fallout against the SportSuite Vision milestone. The stock now trades at US$270.01, and the 1-year total shareholder return of down 29.84% alongside a 5-year total shareholder return of 3.00% suggests fading momentum rather than a steady climb.
Scan beyond Stryker and see how other medical technology players are priced after recent volatility by reviewing our hand picked list of solid balance sheet and fundamentals (23 results).
Bulls view Stryker’s cyber setback as temporary and the SportSuite Vision launch as a new opportunity. Bears focus on a broken trend and fading returns. Which side does the current valuation favor?
Most Popular Narrative: 13.2% Undervalued
The most followed Stryker narrative pegs fair value at $311.21, above the last close of $270.01, which frames the recent sell off very differently.
Stryker is my defensive-growth anchor: a high-quality medtech leader in orthopaedics, surgical equipment and MedSurg, riding the durable tailwind of an ageing population. Demographics, not hype, drive this thesis.
Want to see what keeps that fair value above the current share price? The narrative leans on steady top line expansion, rising margins, and a premium earnings multiple usually reserved for faster growing sectors.
Result: Fair Value of $311.21 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
Still, Stryker’s thesis can crack if hospital spending tightens after the cyberattack, or if acquisitions strain margins instead of reinforcing its MedSurg and orthopaedics engines.
Find out about the key risks to this Stryker narrative.
Next Steps
If this Stryker story feels finely balanced between risk and opportunity, consider acting while sentiment is still unsettled and take time to weigh the full picture for yourself. To see both sides laid out clearly, review the 4 key rewards and 2 important warning signs.
Ready for more Stryker sized ideas?
If you stop with Stryker, you risk missing other clear setups across the market. Put a few minutes into scanning fresh opportunities with these screens.
- Target strong returns with quality businesses that may trade below their estimated worth by running the 33 high quality undervalued stocks.
- Lock in potential income streams by focusing on companies with higher yields and resilient cash generation through the 6 dividend fortresses.
- Prioritise resilience and capital protection by filtering for financially robust businesses using the 11 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com